Biotech Values

[DewDiligence]

> GTCB – Does approval change short term burn? …Guidance prior to approval was that current available funds will keep the juice flowing through the year. Any chance that the CHMP ruling will affect strategy in a way that will increase burn?

EMEA approval will lessen cash burn because:

1. There’s an additional $3M milestone coming from Leo (#msg-8496664);
2. Leo pays 100% of the ATryn development and marketing costs in Europe;
3. GTC will have cash coming in from ATryn product sales in the second half of the year (#msg-8496664).

>Any chance [GTC will] decide to accelerate other programs and need to raise money to do so (including accelerating the ATryn program in Japan)?<

I don’t think GTC will accelerate any programs in a material way on the company’s own dime. The U.S. ATryn program is already moving ahead as fast as it can and more money wouldn’t make any difference.

In Japan, GTC will seek an ATryn partner willing to pay for the clinical development. Regards, Dew